• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Pharma

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

byDeepti Shroff, DMD, MS
May 4, 2026
in Pharma, Public Health
Reading Time: 4 mins read
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Share on FacebookShare on TwitterShare on LinkedIn

Geopolitical instability in the Strait of Hormuz threatens global generic drug supply

Ongoing escalations in the Strait of Hormuz have triggered a sharp drop in maritime shipping through the region, putting pressure on the global pharmaceutical supply chain. While the corridor is best known as a petroleum chokepoint, the United States Pharmacopeia (USP) warned on April 7, 2026, that it also remains a critical transit hub for active pharmaceutical ingredients and finished generics. Disruptions are already affecting regional production and shipment flows, with delays touching commonly used products such as amoxicillin oral suspension and flumazenil API. According to supply chain analysts, the conflict has also reduced air cargo capacity, raising concern for cold chain biologics and insulin. This kind of disruption can travel farther and faster than it first appears. Some products will likely feel the pressure sooner than others depending on inventory depth. A further tightening of shipping routes, as outlined by Think Global Health, could make shortages and pricing pressure more visible in the U.S. by early May.

Revolution’s daraxonrasib demonstrates unprecedented survival in pancreatic cancer
Revolution Medicines announced positive topline results from the Phase 3 RASolute 302 trial on April 13, 2026, showing that daraxonrasib nearly doubled survival in previously treated metastatic pancreatic cancer. In the intent to treat population, the RAS(ON) multi selective inhibitor delivered a median overall survival of 13.2 months compared with 6.7 months for standard chemotherapy. Updated data presented at the AACR Annual Meeting on April 21 also showed a strong objective response rate when used in combination therapy. These results stand out in a disease where progress has historically been limited. The consistency of the benefit across groups has also drawn attention. The company plans to submit these findings to the FDA. Experts at Dana Farber have described this as a meaningful advance for a population with limited treatment options.

FDA grants full approval to sparsentan (Filspari) as first ever treatment for focal segmental glomerulosclerosis (FSGS)
The FDA granted full approval to sparsentan (Filspari) on April 13, 2026, for the reduction of proteinuria in adult and pediatric patients with focal segmental glomerulosclerosis. As the first approved therapy specifically for this rare kidney disease, it represents a major shift in treatment. Phase 3 DUPLEX study data showed rapid and sustained reductions in proteinuria compared with irbesartan. This aligns with the broader move toward disease specific treatment strategies. The expanded FDA indication includes patients aged 8 and older without nephrotic syndrome. Common adverse reactions include peripheral edema, hypotension, and hyperkalemia. Long term outcomes will be important to monitor as use expands.

Glucagon-like peptide-1 (GLP-1) receptor agonists linked to reduced risk of substance use disorders
A large cohort study of more than 600,000 U.S. veterans suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may reduce cravings across multiple addictive substances. Use of these medications was associated with a lower risk of developing new substance use disorders compared with sodium-glucose cotransporter-2 inhibitors. Risk reductions were observed across opioids, nicotine, and cocaine. The findings add to growing evidence that these drugs may influence reward pathways in the brain. Patients often report reduced cravings beyond food, which may reflect this mechanism. The WashU Medicine report also noted fewer overdoses among those with pre existing conditions. A BMJ study provides additional context for these findings. More research will be needed to confirm whether these medications can be used directly in addiction treatment.

Lilly’s orforglipron (Foundayo) launches with no food restrictions
The FDA has approved orforglipron (Foundayo), the first non peptide oral glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. Approved on April 1, 2026, and available through LillyDirect, the tablet can be taken without food or water restrictions. Clinical trials showed an average weight loss of 12.4% at the highest dose. This flexibility may make treatment easier for many patients compared with injectable options. It also removes one of the more inconvenient dosing requirements seen with earlier oral therapies. The FDA accelerated decision made this one of the fastest approvals in recent years. Real world adoption will likely depend on cost, access, and tolerability.

RELATED REPORTS

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial

Image: PD

Drug pageRasonque (daraxonrasib), approved Aug 26, 2026. Indication, pivotal trial and safety at a glance.→
Drug pageFoundayo (orforglipron), approved Apr 1, 2026. Indication, pivotal trial and safety at a glance.→

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: active pharmaceutical ingredientsaddiction researchdaraxonrasibFDA approvalsfocal segmental glomerulosclerosisgeneric drug supplyglucagon-like peptide-1 receptor agonistsoral weight loss therapyOrforglipronpancreatic cancersparsentansubstance use disorder
Previous Post

Near-point-of-care molecular test accurately detects pulmonary tuberculosis

Next Post

Rising amputation rates, especially among opioid-related hospitalizations

RelatedReports

A stylized illustration featuring the pancreas and kidney, with visual elements suggesting pain and chemotherapy effects, related to pancreatic cancer treatment.
Artificial Intelligence

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

October 30, 2026
An illustration of the pancreas, highlighting cancer cells related to pancreatic cancer and molecular structures, indicating targeted research in oncology.
2MM Trial Briefs

Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial

October 25, 2026
The image features a woman examining samples under a microscope, representations of cancer cells, a knee joint, and a liver with a pill at the center, suggesting a focus on oncology and pharmaceutical therapy.
Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
A variety of pharmaceutical items including a vial, capsule, molecule model, pill blister pack, petri dish with a pipette, and a graph, symbolizing drug development.
Pharma Roundup

2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome

September 15, 2026
Next Post
Opioid prescribing collage: a calm man beside an amber pill bottle spilling white tablets onto a pill-counting tray

Rising amputation rates, especially among opioid-related hospitalizations

Migraine collage: a woman with her eyes closed and soft arcs radiating from her temple, a glass of water and a sleep mask

Calcitonin gene-related peptide therapies effective for chronic migraine

Long-term illness care collage: a smiling older man in a wool cardigan beside a potted fern and a steaming cup of tea

Limited pharmacotherapy initiation during veteran hospitalizations for alcohol use disorder

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states
  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.